Peter S. Garcia
Net Worth
Last updated:
What is Peter S. Garcia net worth?
The estimated net worth of Mr. Peter S. Garcia is at least $10,735,123 as of 13 Jun 2024. He owns shares worth $106,015 as insider, has earned $6,540,858 from insider trading and has received compensation worth at least $4,088,250 in ALX Oncology Holdings Inc..
What is the salary of Peter S. Garcia?
Mr. Peter S. Garcia salary is $817,650 per year as Chief Financial Officer in ALX Oncology Holdings Inc..
How old is Peter S. Garcia?
Mr. Peter S. Garcia is 63 years old, born in 1962.
What stocks does Peter S. Garcia currently own?
As insider, Mr. Peter S. Garcia owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | Chief Financial Officer | 122,348 | $0.87 | $106,015 |
What does ALX Oncology Holdings Inc. do?
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Peter S. Garcia insider trading
ALX Oncology Holdings Inc.
Mr. Peter S. Garcia has made 10 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he purchased 12,000 units of ALXO stock worth $102,336 on 13 Jun 2024.
The largest trade he's ever made was exercising 60,000 units of ALXO stock on 23 Aug 2021. As of 13 Jun 2024 he still owns at least 122,348 units of ALXO stock.
ALX Oncology Holdings key executives
ALX Oncology Holdings Inc. executives and other stock owners filed with the SEC:
- Dr. Corey S. Goodman Ph.D. (74) Independent Executive Chairman
- Dr. Jaume Pons Ph.D. (59) Pres, Chief Executive Officer & Director
- Dr. Sophia Randolph M.D., Ph.D. (57) Chief Medical Officer & Director
- Mr. Peter S. Garcia (63) Chief Financial Officer